VM-1500A-LAI

DRUG3 trials

Sponsors

Viriom

Conditions

HIV-1-infection

Phase 1

Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects

CompletedNCT03706911

ViriomHIV-1-infection

Start: 2019-01-21End: 2020-05-18Updated: 2021-12-15

Open Labelled, Randomized Study to Evaluate the Efficacy, Safety and Dose Selection of VM-1500A-LAI Drug in HIV-infected Patients Transferred From Previous Stable Therapy (NNRTI + 2NRTI), Including ELPIDA®

CompletedNCT05163535

ViriomHIV-1-infection

Start: 2021-01-19End: 2021-08-03Updated: 2022-01-11

Phase 2

Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy

ViriomHIV-1-infection

Start: 2022-04-01End: 2023-10-16Target: 438Updated: 2022-01-24